Close
Launched in 2014, the Centre for Doctoral Training (CDT) in Advanced Therapeutics & Nanomedicines is a collaboration between the Schools of Pharmacy at The University of Nottingham and University College London (UCL). Funded by the Engineering and Physical Sciences Research Council (EPSRC) and in partnership with industry sponsors Alliance Boots, AstraZeneca, GlaxoSmithKline, and Pfizer, the CDT in Advanced Therapeutics & Nanomedicines trains PhD students at the cutting-edge of pharmaceutical science.
It builds on the success of the CDT in Targeted Therapeutics, which was launched in 2005 and funded by the EPSRC as the first CDT with direct collaboration from an industry partner (AstraZeneca). In 2012 the CDT expanded as the University of Nottingham and AstraZeneca were joined in partnership by University College London’s School of Pharmacy and five additional industry partners: Alliance Boots, Pfizer, GlaxoSmithKline, Quotient Clinical, and Molecular Profiles.
Programme structure: The Centre for Doctoral Training offers a 4-year Doctoral Training Programme that involves a series of training projects and modules in the first year of study before undertaking a full PhD project. The Doctoral Training Programme link scientists from across the academic and industrial skills bases, to ensure that the training is inherently interdisciplinary. Read more about the CDT programme structure.
Listen to the students of the Centre for Doctoral Training at University College London and University of Nottingham talking about the PhD programme and their experience.
How to apply and further information: The application process for Autumn 2016 is now open.
To read more about the CDT in Advanced Therapeutics and Nanomedicines visit the official CDT website.
Please contact Sarah Marks (UCL) or Claudia Matz (Nottingham) for more information on the programme.